- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00042822
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have myelodysplastic syndrome, acute myeloid leukemia, or non-Hodgkin's lymphoma.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
OBJECTIVES:
- Determine the pattern of adverse clinical experience in patients with myelodysplastic syndrome, acute myeloid leukemia, or intermediate-grade or follicular non-Hodgkin's lymphoma treated with FR901228 (depsipeptide).
- Determine the disease response in patients treated with this drug.
- Determine the pharmacokinetic and pharmacodynamic correlates of this drug, including measurement of serum plasma levels, H3 and H4 acetylation, apoptosis induction, differentiation, and multidrug-resistant (MDR) phenotype expression in these patients.
OUTLINE: Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1 and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed monthly.
PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 1 year.
Studietype
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
One of the following diagnoses:
Histologically confirmed refractory or relapsed acute myeloid leukemia (AML)
- Failed anthracycline-based chemotherapy
- Ineligible for or refused allogeneic stem cell transplantation
Elderly patients with newly diagnosed AML
- Ineligible for or refused standard chemotherapy
Histologically confirmed high-risk myelodysplastic syndromes
Eligible subtypes include:
- Refractory anemia with excess blasts (RAEB)
- RAEB in transformation
- Chronic myelomonocytic leukemia
- Ineligible for or refused allogeneic bone marrow transplantation
Histologically confirmed intermediate-grade non-Hodgkin's lymphoma (NHL)
- Relapsed after high-dose therapy OR
- Ineligible for allogeneic or autologous stem cell transplantation
- Evaluable lesions by radiologic study or physical examination
Histologically confirmed follicular NHL
- Progressed after anthracycline-based chemotherapy and rituximab
- Evaluable lesions by radiologic study or physical examination NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Karnofsky 60-100%
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Bilirubin no greater than 1.5 mg/dL (unless due to Gilbert's syndrome)
- SGOT and SGPT less than 2 times upper limit of normal
Renal
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 60 mL/min
Cardiovascular
- Cardiac ejection fraction greater than 50%
- No cardiac hypertrophy
- No known conduction heart disease
- No New York Heart Association class III or IV heart disease that would make it difficult to assess patient during study participation
- No significant prior heart disease
- No significant prior secondary or tertiary heart block
- No significant prior atrial or ventricular arrhythmia requiring therapeutic intervention or antiarrhythmics for rate control
Pulmonary
- No severe debilitating pulmonary disease that would make it difficult to assess patient during study participation
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 1 month after study participation
- Potassium ≥ 4.0 mmol/L (supplementation allowed)
- Magnesium ≥ 2.0 mg/dL (supplementation allowed)
- No other concurrent active malignancy except basal cell skin cancer
- No other concurrent significant co-morbidity that would make it difficult to assess patient during study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- At least 2 weeks since prior epoetin alfa or filgrastim (G-CSF)
- At least 4 weeks since prior cytokines
- No concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- At least 4 weeks since prior systemic chemotherapy
- No other concurrent chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- At least 4 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery
- Not specified
Other
- No other concurrent investigational agents
No concurrent drugs that may prolong the QTc interval
- FR901228 (depsipeptide) may be administered after a 5-half-life washout period following the use of these drugs
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Virginia Klimek, MD, Memorial Sloan Kettering Cancer Center
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- tilbakevendende grad 3 follikulær lymfom
- tilbakevendende voksent diffust storcellet lymfom
- refraktær anemi med overflødig blaster
- refraktær anemi med overskytende blaster i transformasjon
- kronisk myelomonocytisk leukemi
- tidligere behandlede myelodysplastiske syndromer
- sekundære myelodysplastiske syndromer
- akutt myeloid leukemi hos voksne med 11q23 (MLL) abnormiteter
- akutt myeloid leukemi hos voksne med inv(16)(p13;q22)
- akutt myeloid leukemi hos voksne med t(15;17)(q22;q12)
- akutt myeloid leukemi hos voksne med t(16;16)(p13;q22)
- akutt myeloid leukemi hos voksne med t(8;21)(q22;q22)
- tilbakevendende akutt myeloid leukemi hos voksne
- ubehandlet akutt myeloid leukemi hos voksne
- tilbakevendende voksent diffust små spaltet celle lymfom
- tilbakevendende voksent diffust blandet celle lymfom
- tilbakevendende grad 1 follikulær lymfom
- tilbakevendende grad 2 follikulær lymfom
- myelodysplastisk/myeloproliferativ neoplasma, ikke klassifiserbar
- atypisk kronisk myeloid leukemi, BCR-ABL1 negativ
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesykdommer
- Immunproliferative lidelser
- Sykdom
- Benmargssykdommer
- Hematologiske sykdommer
- Forstadier til kreft
- Lymfom
- Syndrom
- Myelodysplastiske syndromer
- Leukemi
- Preleukemi
- Myeloproliferative lidelser
- Myelodysplastiske-myeloproliferative sykdommer
- Antineoplastiske midler
- Antibiotika, antineoplastisk
- Romidepsin
Andre studie-ID-numre
- CDR0000069473
- MSKCC-00116
- NCI-1715
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på romidepsin
-
CelgeneFullførtKarsinom, nyrecelle | Prostatiske neoplasmerForente stater, Storbritannia
-
CelgeneFullførtKarsinom, nyrecelle | Neoplasma MetastaseForente stater
-
National Cancer Institute (NCI)Fullført
-
National Cancer Institute (NCI)FullførtLymfomForente stater
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Fullført
-
National Cancer Institute (NCI)FullførtGastrointestinal stromal svulst | Tilbakevendende bløtvevssarkom hos voksne | Stage III Bløtvevssarkom for voksne | Stage IV Bløtvevssarkom for voksne | Tilbakevendende Ewing-sarkom/perifer primitiv nevroektodermal svulst | Voksen rabdomyosarkom | Metastatisk Ewing-sarkom/perifer primitiv nevroektodermal... og andre forhold
-
National Cancer Institute (NCI)AvsluttetNeoplasmer | Mycosis Fungoides | Kutant T-celle lymfomForente stater
-
University of ChicagoNational Cancer Institute (NCI)TilbaketrukketEggstokkreftForente stater
-
National Cancer Institute (NCI)AvsluttetTilbakevendende voksent diffust storcellet lymfom | Tilbakevendende mantelcellelymfomForente stater
-
National Cancer Institute (NCI)AvsluttetPrimær peritoneal kreft | Tilbakevendende ovarieepitelkreftForente stater